Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04995274 · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo |
| Cohort 2 | EXPERIMENTAL | Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo |
| Dosing Healthy Adult | EXPERIMENTAL | Ascending Doses in Healthy Adult Volunteers |
| Dosing Healthy Elderly | EXPERIMENTAL | Dosing in Healthy Elderly volunteers |
| PF-04995274 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | Single dose 4 period cross-over, placebo insertion, with food effect |
| Optional Cohort 4 | EXPERIMENTAL | Single dose 3 period cross-over with placebo substitution |
| Name | Type | Description |
|---|---|---|
| PF-04995274 | DRUG | Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo |
| 0.1 mg PF-04995274 | DRUG | 0.1 mg PF-04995274, qd, for 14 days or placebo |
| 1 mg PF-04995274 | DRUG | 1 mg PF-04995274, qd, for 14 days or placebo |
| 10 mg PF-04995274 | DRUG | 10 mg PF-04995274, qd, for 14 days or placebo |
| 15 mg PF-04995274 | DRUG | 15 mg PF-04995274, qd, for 14 days or placebo |
| 1.0 mg PF-04995274 | DRUG | 1.0 mg PF-04995274, qd, for 14 days or placebo |
Inclusion Criteria: * For all cohorts, healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pr...
PF-04995274 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It has been studied in healthy volunteers in Phase 1 clinical trials to evaluate its safety, tolerability, and blood levels. The drug is not approved and remains in clinical development.
PF-04995274 is being studied for use in healthy volunteers, primarily to assess its safety, tolerability, and pharmacokinetics. It has not been studied in any patient population or disease indication. All completed trials enrolled healthy adults and elderly volunteers.
PF-04995274 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. Pfizer has sponsored all four clinical trials of this investigational small molecule.
PF-04995274 is in Phase 1 clinical development. All four trials of the drug have been completed, with a total enrollment of 114 healthy volunteers. The drug is investigational and has not received regulatory approval.
PF-04995274 has been studied in four completed Phase 1 trials: NCT01091272 (single dose in healthy adults), NCT01169714 (multiple doses in healthy adult and elderly volunteers), NCT01173757 (PET study of receptor binding in brain), and NCT01193062 (cerebrospinal fluid sAPP-alpha changes). All trials enrolled healthy volunteers.
PF-04995274 is the only name provided for this investigational drug. No alternative names have been reported in the clinical trial records. It is a distinct small molecule being developed by Pfizer.